» Articles » PMID: 32097453

Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012-2016

Overview
Journal Clin Infect Dis
Date 2020 Feb 26
PMID 32097453
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Annual human immunodeficiency virus (HIV) diagnoses in the United States (US) have plateaued since 2013. We assessed whether there is an association between uptake of pre-exposure prophylaxis (PrEP) and decreases in HIV diagnoses.

Methods: We used 2012-2016 data from the US National HIV Surveillance System to estimate viral suppression (VS) and annual percentage change in diagnosis rate (EAPC) in 33 jurisdictions, and data from a national pharmacy database to estimate PrEP uptake. We used Poisson regression with random effects for state and year to estimate the association between PrEP coverage and EAPC: within jurisdictional quintiles grouped by changes in PrEP coverage, regressing EAPC on time; and among all jurisdictions, regressing EAPC on both time and jurisdictional changes in PrEP coverage with and without accounting for changes in VS.

Results: From 2012 to 2016, across the 10 states with the greatest increases in PrEP coverage, the EAPC decreased 4.0% (95% confidence interval [CI], -5.2% to -2.9%). On average, across the states and District of Columbia, EAPC for a given year decreased by 1.1% (95% CI, -1.77% to -.49%) for an increase in PrEP coverage of 1 per 100 persons with indications. When controlling for VS, the state-specific EAPC for a given year decreased by 1.3% (95% CI, -2.12% to -.57%) for an increase in PrEP coverage of 1 per 100 persons with indications.

Conclusions: We found statistically significant associations between jurisdictional increases in PrEP coverage and decreases in EAPC independent of changes in VS, which supports bringing PrEP use to scale in the US to accelerate reductions in HIV infections.

Citing Articles

Implementation and Evaluation of a Home-Based Pre-Exposure Prophylaxis Monitoring Option: Protocol for a Randomized Controlled Trial.

Cannon C, Holzhauer K, Golden M JMIR Res Protoc. 2024; 13:e56587.

PMID: 39312771 PMC: 11459110. DOI: 10.2196/56587.


Claims-Based Algorithm to Identify Pre-Exposure Prophylaxis Indications for Tenofovir Disoproxil Fumarate and Emtricitabine Prescriptions (2012-2014): Validation Study.

Sullivan P, Mera-Giler R, Bush S, Shvachko V, Sarkodie E, OFarrell D JMIR Form Res. 2024; 8:e55614.

PMID: 39141024 PMC: 11574499. DOI: 10.2196/55614.


HIV PrEP Coverage Among Black Adults: A Concept Analysis of the Inequities, Disparities, and Implications.

Odii I, Vance D, Patrician P, Dick T, Wise J, Corcoran J Health Equity. 2024; 8(1):314-324.

PMID: 39011079 PMC: 11249128. DOI: 10.1089/heq.2023.0250.


Increasing pre-exposure prophylaxis (PrEP) in primary care: A study protocol for a multi-level intervention using the multiphase optimization strategy (MOST) framework.

Lockhart E, Turner D, Guastaferro K, Szalacha L, Alzate H, Marhefka S Contemp Clin Trials. 2024; 143:107599.

PMID: 38848935 PMC: 11812645. DOI: 10.1016/j.cct.2024.107599.


Leveling Up PrEP: Implementation Strategies at System and Structural Levels to Expand PrEP Use in the United States.

Rutstein S, Muessig K Curr HIV/AIDS Rep. 2024; 21(2):52-61.

PMID: 38517670 PMC: 11829776. DOI: 10.1007/s11904-024-00697-x.


References
1.
Khurana N, Yaylali E, Farnham P, Hicks K, Allaire B, Jacobson E . Impact of Improved HIV Care and Treatment on PrEP Effectiveness in the United States, 2016-2020. J Acquir Immune Defic Syndr. 2018; 78(4):399-405. DOI: 10.1097/QAI.0000000000001707. View

2.
Iwuji C, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F . Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV. 2017; 5(3):e116-e125. DOI: 10.1016/S2352-3018(17)30205-9. View

3.
Montaner J, Lima V, Barrios R, Yip B, Wood E, Kerr T . Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010; 376(9740):532-9. PMC: 2996043. DOI: 10.1016/S0140-6736(10)60936-1. View

4.
Phillips A, Cambiano V, Miners A, Lampe F, Rodger A, Nakagawa F . Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. AIDS. 2015; 29(14):1855-62. PMC: 5515630. DOI: 10.1097/QAD.0000000000000767. View

5.
Grulich A, Guy R, Amin J, Jin F, Selvey C, Holden J . Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018; 5(11):e629-e637. DOI: 10.1016/S2352-3018(18)30215-7. View